)
Andrew J. Hall, MD
CEO
Consano Bio
Andrew Hall brings significant experience as a company builder, dealmaker and drug developer in the biotechnology industry. Andrew previously led IMV Inc., a clinical-stage biopharmaceutical company in oncology that was acquired in 2023. Before IMV, Andrew spent 7 years at Celgene, where he led corporate development and pipeline strategy for immunology, as well as business development and strategic alliances, working on deals from discovery to commercialization.
Andrew also spent more than 15 years at Merck, BMS and Schering Plough in leadership roles across Asia Pacific, Europe and the United States. Through all these experiences, Andrew has developed expertise across multiple disease spaces, major geographies and end-to-end drug development. Andrew holds a Master of Science from RMIT University and a Bachelor of Medical Science (honors) from Melbourne University.
Sessions
-
22-Jun-2026Theater 1Consano Bio
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}